Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02470897
Recruitment Status : Recruiting
First Posted : June 12, 2015
Last Update Posted : May 5, 2020
Sponsor:
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
This phase I/II trial studies the side effects and best dose of stereotactic body radiation therapy while using intensity-modulated radiation therapy (IMRT) planning to help avoid radiation to normal tissue in patients with prostate cancer. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using small, high doses of radiation over several days and may cause less damage to normal tissue. This treatment schedule allows for a higher dose of radiation to be administered over a shorter overall treatment period in comparison to standard radiation therapy.

Condition or disease Intervention/treatment Phase
Stage I Prostate Adenocarcinoma Stage II Prostate Adenocarcinoma Radiation: Radiation Therapy Treatment Planning and Simulation Radiation: SBRT Not Applicable

Detailed Description:

PRIMARY OBJECTIVES:

I. To evaluate the incidence of genitourinary (GU) and gastrointestinal (GI) acute and late toxicity for patients treated with prostate stereotactic body radiotherapy (SBRT) with simultaneous integrative boost, urethral ring sparing, and enhanced prostate localization (magnetic resonance imaging [MRI\-computed tomography [CT] fusion).

II. To also evaluate the incidence of GU and GI acute and late toxicity for patients treated with prostate stereotactic body radiotherapy (SBRT) with a more conventional and uniformly delivered dose of 7.25 Gy/fraction to the prostate.

III. Disease-free survival: disease-free failure events include local progression, distant progression, biochemical failure as defined by the Radiation Therapy Oncology Group (RTOG) Phoenix definition, and death from any cause.

SECONDARY OBJECTIVES:

I. Evaluate patient quality of life (QOL) using the Expanded Prostate Cancer Index Composite 26 (EPIC-26) for evaluation of the QOL for up to 3 years after the completion of SBRT.

OUTLINE: Participants are assigned to 1 of 2 treatment arms. Participants unable to undergo MRI, whose MRI proves technically inadequate for delineating needed anatomic structures, or who decline to enroll on Arm A are assigned to Arm B.

ARM A: (n = 120) Participants undergo 5 fractions of moderate dose SBRT with simultaneous integrated boost (SIB) every other day for 10 days following urethral-sparing IMRT planning.

ARM B: (n = 40) Participants undergo 5 fractions of uniform dose SBRT every other day for 10 days following undergo urethral-sparing IMRT planning.

After completion of study treatment, patients are followed up at 4-6 weeks, at 4, 8, and 12 months, every 4 months for 1 year, every 6 months for 3 years, and then every 12 months thereafter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Simultaneous Integrated Boost and Urethral-Sparing IMRT Planning
Actual Study Start Date : July 24, 2015
Estimated Primary Completion Date : December 2026
Estimated Study Completion Date : December 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Arm A (moderate dose SBRT with SIB)

Patients undergo 5 fractions of moderate dose SBRT with SIB every other day for 10 days following urethral-sparing IMRT planning.

SBRT: 8.0Gy escalated dose

Radiation: Radiation Therapy Treatment Planning and Simulation
Undergo urethral-sparing IMRT planning
Other Name: Radiation Therapy Treatment Planning/Simulation

Radiation: SBRT
Undergo moderate dose SBRT with SIB
Other Name: Stereotactic Body Radiation Therapy

Active Comparator: Arm B (uniform dose SBRT)

Patients undergo 5 fractions of uniform dose SBRT every other day for 10 days following urethral-sparing IMRT planning.

SBRT: 7.5Gy conventional dose

Radiation: Radiation Therapy Treatment Planning and Simulation
Undergo urethral-sparing IMRT planning
Other Name: Radiation Therapy Treatment Planning/Simulation

Radiation: SBRT
Undergo uniform dose SBRT
Other Name: Stereotactic Body Radiation Therapy




Primary Outcome Measures :
  1. Incidence of GU and GI Acute Toxicity [ Time Frame: Up to 90 days ]
    Evaluation of delivering SBRT to the prostate using non-uniform dosing. The investigators will evaluate the potential for any added grade 3 rectal toxicity with the use of a simultaneous integrated boost.

  2. Incidence of GU and GI Late Toxicity [ Time Frame: Up to 60 months ]
    Evaluation of delivering SBRT to the prostate using non-uniform dosing. The investigators will evaluate the potential for any added grade 3 rectal toxicity with the use of a simultaneous integrated boost. A late adverse event will be defined as an adverse event occurring more than 90 days from the completion of RT.

  3. Disease-free survival as measured by the Phoenix definition [ Time Frame: Up to 60 months ]

Secondary Outcome Measures :
  1. Change in Expanded Prostate Cancer Index Composite (EPIC) 26 Quality of Life Assessment [ Time Frame: at Baseline, 1 year, and 2 years ]
    The EPIC 26 assessment has a total range of possible scores of 1-100 where higher scores indicate higher satisfaction. Questionnaires will be performed prior to treatment, and one and two years after completion of treatment.

  2. Change in American Urological Association Symptom Score (AUASS) [ Time Frame: at Baseline, 1 year, and 2 years ]
    The AUASS has a total possible range of scores of 0-35 where 1-7 is considered mild symptoms, 8-19 is considered moderate symptoms, and 20-35 is considered severe symptoms. Questionnaires will be performed prior to treatment, and one and two years after completion of treatment.

  3. Change in International Index of Erectile Dysfunction Questionnaire (IIEF-5) [ Time Frame: at Baseline, 1 year, and 2 years ]
    The IIEF-5 questionnaire has a total score of 1-25 where 1-7 is considered severe erectile dysfunction (ED), 8-11 is moderate ED, 12-16 is mild-moderate ED, 17-21 is mild ED, and 22-25 is no ED. Questionnaires will be performed prior to treatment, and one and two years after completion of treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of adenocarcinoma of the prostate and most recent biopsy within 180 days of study enrollment
  • History/physical examination with digital rectal examination of the prostate within 90 days prior to study enrollment
  • Gleason score =< 7, no tertiary pattern >= 5
  • Clinical stage =< T2b (American Joint Committee on Cancer [AJCC] 7th Edition Staging Manual) and no radiographic evidence of T3 or T4 disease
  • Clinical stage N0, M0
  • Most recent prostate specific antigen (PSA) within 60 days of enrollment
  • Maximum PSA =< 20 ng/ml (not within 20 days after biopsy)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • American Urological Association (AUA) =< 18 with or without medical management
  • Up to a total of year of androgen deprivation allowed.
  • Participant signs study specific informed consent prior to study enrollment
  • Confirmation that insurance will cover SBRT through normal hospital authorization process

Exclusion Criteria:

  • FOR ARM A: Inability to obtain a planning MRI or a planning MRI of sufficient quality to allow identification of the peripheral zone and urethra, or inability to adequately fuse the MRI to the planning CT scan
  • FOR BOTH ARM A AND ARM B:
  • Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5 years; (for example, carcinoma in situ of the bladder or oral cavity is permissible)
  • Prosthetic implants in the pelvic region that the investigator feels will impede treatment, planning, or delivery (e.g., an artificial hip)
  • =< 3 months from a transurethral resection of the prostate (TURP) procedure
  • Significant urinary obstruction (i.e. AUA symptom score > 18)
  • Previous pelvic irradiation, prostate brachytherapy
  • Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
  • Severe, active comorbidity, defined as follows:

    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
    • Crohn's disease or ulcerative colitis
    • Scleroderma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02470897


Contacts
Layout table for location contacts
Contact: Cancer Connect (800) 622-8922 clinicaltrials@cancer.wisc.edu

Locations
Layout table for location information
United States, Illinois
Swedish American Not yet recruiting
Rockford, Illinois, United States, 61104
Contact: Cancer Connect    800-622-8922      
United States, Wisconsin
UW Cancer Center, Johnson Creek Recruiting
Johnson Creek, Wisconsin, United States, 53038
Contact: Cancer Connect    800-622-8922      
University of Wisconsin Carbone Cancer Center Recruiting
Madison, Wisconsin, United States, 53792
Contact: Cancer Connect    800-622-8922    clinicaltrials@cancer.wisc.edu   
Principal Investigator: Zachary Morris         
Sponsors and Collaborators
University of Wisconsin, Madison
Investigators
Layout table for investigator information
Principal Investigator: Zachary Morris University of Wisconsin, Madison
Additional Information:
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT02470897    
Other Study ID Numbers: UW14083
NCI-2015-00950 ( Registry Identifier: NCI Trial ID )
2015-0395 ( Other Identifier: Institutional Review Board )
UW14083 ( Other Identifier: University of Wisconsin Carbone Cancer Center )
A533300 ( Other Identifier: UW Madison )
SMPH\HUMAN ONCOLOGY\HUMAN ONCO ( Other Identifier: UW Madison )
First Posted: June 12, 2015    Key Record Dates
Last Update Posted: May 5, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Adenocarcinoma
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type